Меню
Идёт набор NCT06692894

Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Наблюдательное Myelodysplastic Syndromes, Adult

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Observational.
Кому может быть актуально
Состояния в реестре: Myelodysplastic Syndromes, Adult. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Обзор

Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS

Подробное описание

What Is Involved in The Study?

* This study will follow patients with MDS over 6 months. * Participants will come to the hospital for the first visit. Participants will learn about the study, sign papers to join the study, and share some basic health information. Participants will also give a blood sample of 10 milliliters after not eating overnight. * After the first visit, participants will come back to the hospital once a week for 3 weeks to give more blood samples after fasting overnight. * The study team will call participants the day before each scheduled blood draw to remind you of your appointment. * Then participants will return to the hospital for another visits once a month for the next 5 months. Participants will talk about any changes in their health and give a blood sample at each visit. * Participants won't get any treatment as part of this study, but their participation will help researchers learn how inflammation affects the health of people with MDS * Researchers will collect a small amount of blood (6-10 mL) per visit * These blood collections are a normal part of medical care and won't require participants to come in more often than usual. The frequency of visits will be part of the routine care for myelodysplastic syndrome at the cancer center. Extra blood will be collected during standard of care blood draws in the clinic. * Sessions will take about 20 minutes.

Вмешательства

  • Другое Observational
    Blood will be collected from one cohort to identify potential blood biomarkers.

Первичные конечные точки

  • Biologic Variability of Markers of Inflammation in the Blood [Срок оценки: over 6 months]

Критерии участия

Критерии включения

  • Age ≥18 years
  • Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤3
  • Expected survival of at least 6 months
  • Ability to provide consent

Критерии исключения

  • Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis
  • Hematopoietic stem cell transplantation expected within 6 months

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Только случаи

Центры проведения

США · 1 центр
  • University of Vermont — Burlington

Идентификаторы

NCT: NCT06692894 · STUDY00003256/UVMCC2406

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗